VBI Vaccines has entered into a research collaboration with Sanofi Pasteur to apply VBI's LPV (Lipid Particle Vaccine) formulation technology to further the development of a key Sanofi Pasteur vaccine candidate.
Under the collaboration agreement, Sanofi Pasteur will leverage VBI's LPV technology and expertise to reformulate a Sanofi Pasteur vaccine candidate to provide improved stability.
|Searching for more deal information? Current Partnering offers the following options:
- CP Reports | Browse titles | Over 200 report titles that focus upon different deal types from licensing, co-promotion to distribution, biomarkers to drug delivery, oncology to psychiatry, all of which provide you with an insight into the latest life science deal making trends
- Current Agreements | Login | Find out more | Updated daily by our industry analysts, our fully searchable life sciences intelligence database allows you to find deals and alliances dating as far back as 2000 saving you valuable time on your deal making research activities
- CP Knowledge Centre | Login | Find out more | Provides you with an all-in-one intelligence package that allows you to simultaneously access our CP reports, CP Insight and Current Agreements deal and alliances database, at the same time
The collaboration provides Sanofi Pasteur with the option to acquire certain worldwide rights to use VBI's LPV technology in its vaccines.
The vaccine candidate and the terms of the agreement were not disclosed.
For further deal information visit Current Agreements (subscription required)
Scorecard: Top partnering deals by value in 2015
View: Top pharmaceutical companies
View: Top biotech companies
Reports: Browse our extensive deal making report portfolio